SCHEMBL2535689

SCHEMBL2535689

CN1C=CC(c2c3nc(c(C4=CCN(C)C=C4)c4ccc([nH]4)c(-c4ccccc4)c4nc(c(-c5ccccc5)c5ccc2[nH]5)C=C4)C=C3)=CC1

nearest known ligand 0.47

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.47
STAT3 P40763 1/20 0.43
STAT1 P42224 1/20 0.43
TOP1 P11387 4/20 0.43
CYCS P99999 3/20 0.42
ENPP2 Q13822 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759942 1.00 TERT (0.47) TERTSTAT3STAT1TOP1CYCS
SCHEMBL9438544 1.00 TERT (0.47) TERTSTAT3STAT1TOP1CYCS
SCHEMBL7150430 1.00 TERT (0.47) TERTSTAT3STAT1TOP1CYCS
Hydrochloric Acid SCHEMBL8182742 0.99 TERT (0.46) TERTSTAT3STAT1TOP1CYCS
Hydrochloric Acid SCHEMBL8182065 0.99 TERT (0.46) TERTSTAT3STAT1TOP1CYCS
SCHEMBL18418 0.91 TERT (0.44) TERTTOP1CYCSENPP2
Hydrochloric Acid SCHEMBL7246124 0.90 TERT (0.43) TERTTOP1CYCSENPP2
Hydrochloric Acid SCHEMBL4138914 0.90 TERT (0.43) TERTTOP1CYCSENPP2
Hydrochloric Acid SCHEMBL30474599 0.90 TERT (0.43) TERTTOP1CYCSENPP2
SCHEMBL2375486 0.90 TERT (0.43) TERTTOP1CYCSENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5281616-A Treatment of human immunodeficiency virus infections GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1994-01-25 US claimed
US-5192788-A PORPHYRIN ANTIVIRAL COMPOSITIONS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1993-03-09 US claimed
US-5109016-A Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1992-04-28 US claimed
WO-1989011277-A2 PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1989-11-30 WO claimed
CN-114948801-A Protective composition with relieving effect and preparation method thereof 深圳减字科技有限公司 2022-08-30 CN disclosed
US-10888569-B1 Methods and compositions for treating cancer THE UNIVERSITY OF CHICAGO (US) 2021-01-12 US disclosed
US-20110253197-A1 TUNED SOLAR CONCENTRATORS AND DEVICES AND METHODS USING THEM MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-10-20 US disclosed
US-20100193011-A1 MATERIALS FOR SOLAR CONCENTRATORS AND DEVICES, METHODS AND SYSTEM USING THEM ENERGY, UNITED STATES DEPARTMENT OF 2010-08-05 US disclosed
WO-2010085561-A2 MATERIALS FOR SOLAR CONCENTRATORS AND DEVICES, METHODS AND SYSTEMS USING THEM MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-07-29 WO disclosed
US-20050192209-A1 Eosinophil Major Basic Protein as a natural heparanase-inhibiting protein, compositions, methods and uses thereof UNIVERSITY OF UTAH RESEARCH FOUNDATION 2005-09-01 US disclosed
US-20050090428-A1 Porphyrins with virucidal activity EMORY UNIVERSITY (US) 2005-04-28 US disclosed
US-6716794-B2 PHOTOSENSITIZERS OF THE TETRAPYRROL AND/OR TETRAAZOPYRROL FAMILIES HAVING AT LEAST ONE POSITIVE CHARGE AT A SUBSTITUENT FOR CONTROLLING BACTERIAL GERMS AND ALGAE IN AQUARIA DPC D.O.O. (SI) 2004-04-06 US disclosed
US-6454951-B1 TETRAPYRROLE AND/OR TETRAAZAPYRROLE COMPOUND, WATER SWELLABLE SOLID CARRIER SELECTED FROM POLYSTYRENE, SEPHADEX AND CLAY, Jori, Giulio (IT) 2002-09-24 US disclosed
EP-0894011-A2 DELIVERY OF NUCLEIC ACIDS BY PORPHYRINS INNOVIR LABORATORIES, INC. (US) 1999-02-03 EP disclosed
WO-1998006440-A2 PHENOTYPIC CONVERSION OF CELLS MEDIATED BY EXTERNAL GUIDE SEQUENCES INNOVIR LABORATORIES, INC. (US) 1998-02-19 WO disclosed
WO-1997033622-A2 DELIVERY OF NUCLEIC ACIDS BY PORPHYRINS INNOVIR LABORATORIES, INC. (US) 1997-09-18 WO disclosed
US-5281616-A Treatment of human immunodeficiency virus infections GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1994-01-25 US disclosed
US-5192788-A PORPHYRIN ANTIVIRAL COMPOSITIONS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1993-03-09 US disclosed
US-5109016-A Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1992-04-28 US disclosed
WO-1989011277-A2 PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1989-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090428-A1 Porphyrins with virucidal activity ZP1, MAVS, VIP TERT 869/4885STAT3 3292/4885STAT1 2812/4885
US-10888569-B1 Methods and compositions for treating cancer BACH1, BCOR, BCCIP TERT 190/4885STAT3 728/4885STAT1 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.